Erythrocyte Carbonic Anhydrase-I Concentrations in Patients with Graves’ Disease and Subacute Thyroiditis Reflect Integrated Thyroid Hormone Levels over the Previous Few Months*

1991 ◽  
Vol 72 (2) ◽  
pp. 515-518 ◽  
Author(s):  
YOSHINORI KISO ◽  
KATSUMI YOSHIDA ◽  
KAZURO KAISE ◽  
NOBUKO KAISE ◽  
HIROSHI FUKAZAWA ◽  
...  
Keyword(s):  
Thyroid Hormone ◽  
Carbonic Anhydrase ◽  
Subacute Thyroiditis ◽  
Graves Disease ◽  
Hormone Levels ◽  
Carbonic Anhydrase I ◽  
Thyroid Hormone Levels ◽  
Erythrocyte Carbonic Anhydrase

scholarly journals Rescue pre-operative treatment with Lugol’s solution in uncontrolled Graves’ disease

2017 ◽  
Vol 6 (4) ◽  
pp. 200-205 ◽  
Author(s):  
Jan Calissendorff ◽  
Henrik Falhammar
Keyword(s):  
Heart Rate ◽  
Thyroid Hormone ◽  
Side Effects ◽  
Definitive Treatment ◽  
Graves Disease ◽  
Free T4 ◽  
Hormone Levels ◽  
Free T3 ◽  
Adherence To Medication ◽  
Thyroid Hormone Levels

Background Graves’ disease is a common cause of hyperthyroidism. Three therapies have been used for decades: pharmacologic therapy, surgery and radioiodine. In case of adverse events, especially agranulocytosis or hepatotoxicity, pre-treatment with Lugol’s solution containing iodine/potassium iodide to induce euthyroidism before surgery could be advocated, but this has rarely been reported. Methods All patients hospitalised due to uncontrolled hyperthyroidism at the Karolinska University Hospital 2005–2015 and treated with Lugol’s solution were included. All electronic files were carefully reviewed manually, with focus on the cause of treatment and admission, demographic data, and effects of iodine on thyroid hormone levels and pulse frequency. Results Twenty-seven patients were included. Lugol’s solution had been chosen due to agranulocytosis in 9 (33%), hepatotoxicity in 2 (7%), other side effects in 11 (41%) and poor adherence to medication in 5 (19%). Levels of free T4, free T3 and heart rate decreased significantly after 5–9 days of iodine therapy (free T4 53–20 pmol/L, P = 0.0002; free T3 20–6.5 pmol/L, P = 0.04; heart rate 87–76 beats/min P = 0.0007), whereas TSH remained unchanged. Side effects were noted in 4 (15%) (rash n = 2, rash and vomiting n = 1, swelling of fingers n = 1). Thyroidectomy was performed in 26 patients (96%) and one was treated with radioiodine; all treatments were without serious complications. Conclusion Treatment of uncontrolled hyperthyroidism with Lugol’s solution before definitive treatment is safe and it decreases thyroid hormone levels and heart rate. Side effects were limited. Lugol’s solution could be recommended pre-operatively in Graves’ disease with failed medical treatment, especially if side effects to anti-thyroid drugs have occurred.

Graves' disease: An analysis of thyroid hormone levels and hyperthyroid signs and symptoms

1989 ◽  
Vol 87 (5) ◽  
pp. 558-561 ◽  
Author(s):  
Paula T. Trzepacz ◽  
Irwin Klein ◽  
Michelle Roberts ◽  
Joel Greenhouse ◽  
Gerald S. Levey
Keyword(s):  
Thyroid Hormone ◽  
Signs And Symptoms ◽  
Graves Disease ◽  
Hormone Levels ◽  
Thyroid Hormone Levels

Catatony in Graves' disease

1998 ◽  
Vol 13 (8) ◽  
pp. 419-420 ◽  
Author(s):  
J Rudolf ◽  
M Grond ◽  
M Neveling ◽  
W-D Heiss
Keyword(s):  
Thyroid Hormone ◽  
Psychiatric Symptoms ◽  
Normal Serum ◽  
Prior History ◽  
Graves Disease ◽  
Drug Induced ◽  
Hormone Levels ◽  
Neuroleptic Syndrome ◽  
Serum Thyroid Hormone ◽  
Thyroid Hormone Levels

SummaryWe report a 27-year-old female patient with prior history of Graves' disease and relapsing episodes of tachycardia, hyperpyrexia, muscular rigidity and coma. With the subsequent manifestation of an acute schizophreniform psychotic disorder unresponsive to neuroleptics, the primary syndrome was re-classified as febrile catatony. Hyperthyroidism was ruled out with normal serum thyroid hormone levels, as were toxic effects of thyrostatic treatment, drug-induced hypothyroidism and a malignant neuroleptic syndrome. All psychiatric symptoms subsided completely following subtotal thyroidectomy. Febrile catatatony has to be added to the spectrum of psychotic phenomena that may be caused by Graves' disease, irrespective of serum thyroid hormone levels.

Three basic patterns of changes in serum thyroid hormone levels in Graves’ disease during the one-year period after radioiodine therapy

2005 ◽  
Vol 19 (4) ◽  
pp. 297-308 ◽  
Author(s):  
Masayuki Nakajo ◽  
Shinsaku Tsuchimochi ◽  
Hiroaki Tanabe ◽  
Yoshiaki Nakabeppu ◽  
Megumi Jinguji
Keyword(s):  
Thyroid Hormone ◽  
Radioiodine Therapy ◽  
Graves Disease ◽  
Hormone Levels ◽  
Serum Thyroid Hormone ◽  
Thyroid Hormone Levels ◽  
One Year ◽  
The One

Age Moderates the Impact of TRAbs on Thyroid Hormones and Hepatic Function in Patients with Graves’ Disease

2021 ◽  
Vol 53 (07) ◽  
pp. 453-460
Author(s):  
Kai Guo ◽  
Hongwei Ling ◽  
Xiaoyan Zhou ◽  
Changjiang Ying
Keyword(s):  
Thyroid Hormone ◽  
Thyroid Hormones ◽  
Hepatic Function ◽  
Graves Disease ◽  
Newly Diagnosed ◽  
Younger Patients ◽  
Hormone Levels ◽  
Thyroid Hormone Levels ◽  
Antibody Levels ◽  
The Impact

AbstractThyrotropin receptor antibodies (TRAbs) play a significant role in the course of hepatic dysfunction (HDF) in patients with Graves’ disease (GD). However, few studies have considered the factors that influence the relationships among TRAbs, thyroid hormone levels, and hepatic function in subjects with newly diagnosed GD. Here we investigated the associations of TRAbs with thyroid hormones and hepatic function and assessed potential factors that can influence these associations among patients with GD. A total of 368 patients newly diagnosed with GD were collected in this cross-sectional study. Patients who had received antithyroid drugs, radioactive iodine, or surgery were excluded. Levels of TRAbs and thyroid hormones and hepatic function were recorded. Linear and binary logistic regression analysis models were applied to investigate associations among these variables after adjusting for confounding characteristics. There was a significant difference in TRAbs indices between the HDF and normal hepatic function groups (p <0.05). After adjusting for confounders, the relationship between TRAbs and thyroid hormones was nonlinear, showing a curve with an initial positive slope and a subsequent flattening (p <0.05). Higher TRAbs were associated with HDF [odds ratio (OR) 1.036, 95% confidence interval (CI) 1.018–1.053 per 1-IU/l increase]. These associations were modified by age, but not by gender, smoking status, Graves’ orbitopathy, thyroid-peroxidase antibody levels, or thyroglobulin antibody levels. In younger patients, increasing TRAbs were correlated with higher thyroid hormones and HDF (OR 1.034, 95% CI 1.017–1.052) per1-IU/l increase). In older patients, TRAbs were not correlated with thyroid hormones or HDF (OR 1.024, 95% CI 0.993–1.056) per 1-IU/l increase. Age can affect the impact of TRAbs on thyroid hormone levels and hepatic function in GD. TRAb measurement can have good predictive value in younger patients.

Sign in / Sign up

Export Citation Format

Share Document